Tyramine pressor effect in man: studies with moclobemide, a novel, reversible monoamine oxidase inhibitor.
The pressor effect of tyramine (TYR) administered i.v. and orally was measured in healthy volunteers during treatment with different therapeutic doses of moclobemide, a new, reversible, preferential type A monoamine oxidase inhibitor. With moclobemide 3 X 100 mg/day the systolic blood pressure (SBP) increase produced by TYR administered i.v. was potentiated 2.4-fold and that in response to TYR p.o. in the fasting state was increased 4.1-fold, as determined from equieffective TYR doses before and during moclobemide treatment. Peak concentrations of free TYR in plasma after oral doses of TYR were increased 2.6-fold, and a 2.5-fold smaller plasma TYR concentration produced the same SBP rise as before moclobemide treatment. No SBP increase was observed at plasma TYR concentrations below 20 ng/ml or after p.o. TYR does smaller than 80 mg. The potentiation of the pressor effect of i.v. TYR by single moclobemide doses up to 300 mg had disappeared 24 hrs after moclobemide administration. Peak TYR plasma concentration and concomitant SBP increments were considerably smaller when TYR was administered with a meal than when administered as a bolus with tap water, 2.1 times higher oral TYR doses being required to achieve similar peak TYR plasma concentration as in the fasting condition. The pressor effect of TYR was further, but only slightly, increased during treatment with moclobemide 3 x 200 mg/day, however SBP rises were again significantly smaller when TYR was given together with a meal. In contrast, tranylcypromine produced a 20 to 40-fold potentiation of the pressor effect of oral TYR and this potentiation was only slightly smaller when TYR was given with a meal. In conclusion the potentiation by moclobemide of the pressor response to oral TYR corresponds roughly to a fourfold left shift of the TYR dose-pressor response curve and is about 10 times less marked than after tranylcypromine. In real life situations, the ingestion of TYR in amounts less than 100 mg is highly unlikely to produce a clinically relevant blood pressure elevation.
Korn
A
A
Division of Clinical Pharmacology, I. Medizinische Universitäts-Klinik, Vienna, Austria.
Da Prada
M
M
Raffesberg
W
W
Allen
S
S
Gasic
S
S
D000328:Adult; D001549:Benzamides / Q000008:administration & dosage / Q000009:adverse effects*; D004357:Drug Synergism; D006801:Humans; D006973:Hypertension / Q000139:chemically induced*; D008297:Male; D020912:Moclobemide; D008996:Monoamine Oxidase Inhibitors / Q000009:adverse effects*; D014191:Tranylcypromine / Q000009:adverse effects; D014439:Tyramine / Q000008:administration & dosage / Q000009:adverse effects* / Q000097:blood
D001549:Benzamides; D008996:Monoamine Oxidase Inhibitors; D014191:Tranylcypromine; D020912:Moclobemide; D014439:Tyramine